Home > Riviste > Panminerva Medica > Fascicoli precedenti > Articles online first > Panminerva Medica 2016 Sep 15





Rivista di Medicina Interna

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6



Panminerva Medica 2016 Sep 15

lingua: Inglese

Angiotensin receptor blockers and breast cancer risk: a meta-analysis

Yun F. QIAN, Wei G. XU, Jun WU

Department of Geriatrics, Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China


INTRODUCTION: Some studies reported that Angiotensin receptor blockers (ARBs) reduced the risk of breast cancer. However, other studies did not show similar results.
EVIDENCE ACQUISITION: The Pubmed and Embase databases were searched. The strength of the association between ARBs and the risk of breast cancer was measured by odds ratio (OR) and 95% confidence interval (CI).
EVIDENCE SYNTHESIS: Eight eligible literatures with 1994880 individuals were enrolled in this meta-analysis. ARBs was not associated with the risk of breast cancer (OR=0.93; 95%CI, 0.81–1.06; I2=86%). In the subgroup analysis of race, a significantly decreased breast cancer risk were observed in Asians (OR=0.62; 95%CI, 0.53–0.73; I2=0%). However, a significantly increased breast cancer risk were observed in Caucasians (OR=1.08; 95%CI, 1.02–1.13; I2=28%).
CONCLUSIONS: This study provided evidence that ARBs was associated with decreased breast cancer in Asians and increased risk of breast cancer in Caucasians.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail